BackgroundT1 mapping based on cardiovascular magnetic resonance (CMR) is a novel approach using the magnetic relaxation T1 time as a quantitative marker for myocardial tissue composition. Various T1 mapping sequences are being used, with different strengths and weaknesses. Data comparing different sequences head to head however are sparse.MethodsWe compared three T1 mapping sequences, ShMOLLI, MOLLI and SASHA in phantoms and in a mid-ventricular slice of 40 healthy individuals (mean age 59 ± 7 years, 45 % male) with low (68 %) or moderate cardiovascular risk. We calculated global and segmental T1 in vivo through exponential curve fitting and subsequent parametric mapping. We also analyzed image quality and inter-observer reproducibility.ResultsThere was no association of T1 with cardiovascular risk groups. T1 however differed significantly depending on the sequence, with SASHA providing consistently higher mean values than ShMOLLI and MOLLI (1487 ± 36 ms vs. 1174 ± 37 ms and 1199 ± 28 ms, respectively; p < 0.001). This difference between sequences was much smaller in phantom measurements. In patients, segmental values were lower in the anterior wall for all sequences. Image quality, in general good for the steady-state-free-precession readouts in all sequences, was lower for SASHA parametric maps. On multivariate regression analysis, a longer T1 measured by MOLLI was correlated with lower ejection fraction and female gender. Inter-observer variability as assessed by intra-class correlation coefficients was excellent for all sequences (ShMOLLI: 0.995; MOLLI: 0.991; SASHA: 0.961; all p < 0.001).ConclusionIn a cross-sectional population with low to moderate cardiovascular risk, we observed a variation in T1 mapping results between inversion-recovery vs. saturation-recovery sequences in vivo, which were less evident in phantom images, despite a small interobserver variability. Thus, physiological factors, most likely related to B1 inhomogeneities, and tissue-specific properties, like magnetization transfer, that impact T1 values in vivo, render phantom validation insufficient, and have to be further investigated for a better understanding of the clinical utility of different T1 mapping approaches.Trial registration“Canadian Alliance For Healthy Hearts and Minds” – ClinicalTrials.gov NCT02220582; registered August 18, 2014.

Background: Quantitative cardiovascular magnetic resonance T1-mapping is increasingly used for myocardial tissue characterization. However, the lack of standardization limits direct comparability between centers and wider roll-out for clinical use or trials. Purpose: To develop a quality assurance (QA) program assuring standardized T1 measurements for clinical use. Methods: MR phantoms manufactured in 2013 were distributed, including ShMOLLI T1-mapping and reference T1 and T2 protocols. We first studied the T1 and T2 dependency on temperature and phantom aging using phantom datasets from a single site over 4 years. Based on this, we developed a multiparametric QA model, which was then applied to 78 scans from 28 other multi-national sites. Results: T1 temperature sensitivity followed a second-order polynomial to baseline T1 values (R 2 > 0.996). Some phantoms showed aging effects, where T1 drifted up to 49% over 40 months. The correlation model based on reference T1 and T2, developed on 1004 dedicated phantom scans, predicted ShMOLLI-T1 with high consistency (coefficient of variation 1.54%), and was robust to temperature variations and phantom aging. Using the 95% confidence interval of the correlation model residuals as the tolerance range, we analyzed 390 ShMOLLI T1-maps and confirmed accurate sequence deployment in 90%(70/78) of QA scans across 28 multiple centers, and categorized the rest with specific remedial actions. Conclusions: The proposed phantom QA for T1-mapping can assure correct method implementation and protocol adherence, and is robust to temperature variation and phantom aging. This QA program circumvents the need of frequent phantom replacements, and can be readily deployed in multicenter trials.

Authors' contributions: NA contributed to the design of the study, recruited the patients, interpreted the results and wrote the manuscript. KF provided significant contributions to the design of the study, data interpretation, co-wrote the manuscript and had a significant role in the development of the OS-technique applied to cardiac patients. TH played a significant role in the software development and in the interpretation of the data. He reviewed the manuscript and provided significant feedback to improve the content. MF contributed to the design of the study; had a significant role in the development of the OS-technique applied to cardiac patients and provided the software needed to interpret this data. FPM contributed to the data analysis and interpretations, provided in depth review of the manuscript to improve the intellectual content.MW co-supervised the graduate student (NI) with MF, contributed to recruiting the patients, provided multiple reviews of the manuscript to improve the intellectual content, provided the funding for the realization of the study. Conflict of interestMGF is a board member, advisor and shareholder of Circle Cardiovascular Imaging Inc., the manufacturer of the software used for CMR image evaluation. MGF, and KF were inventors of but no longer hold the international patent: "Measuring oxygenation changes in tissue as a marker

Background: Recent reports have shown that T1 mapping sequences agree in phantoms, but

No abstract

No abstract

No abstract

No abstract